Pharmacokinetics of antiretroviral therapy in HIV-1-infected children

Clinical Pharmacokinetics

Volumn 44, Issue 9, 2005, Pages 935-956

  Fraaij, Pieter L A ^a   Van Kampen, Jeroen J A ^a   Burger, David M ^b   De Groot, Ronald ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; CAUSE OF DEATH; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG LABELING; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PEER REVIEW; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; CHILD; HIV INFECTIONS; HIV-1; HUMANS; PRACTICE GUIDELINES;

EID: 24344447159     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544090-00004     Document Type: Review

References (100)

1. Peeters M, Courgnaud V, Abela B, et al. Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis 2002; 8 (5): 451-7
2. Korber B, Muldoon M, Theiler H, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288 (5472): 1789-96
3. UNAIDS. AIDS epidemic update: 2003. Geneva: UNAIDS/WHO, 2003
4. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998; 279 (10): 756-61
5. Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989; 321 (26): 1791-6
6. de Martino M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001; 15 (12): 1527-34
7. Buehler JW, Berkelman RL, Curran JW. Reporting of AIDS: tracking HIV morbidity and mortality. JAMA 1989; 262 (20): 2896-7
8. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345 (21): 1522-8
9. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853-60
10. Stretcher BN. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995; 29 (1): 46-65
11. Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91 (5): 2326-33
12. Perno CF, Yarchoan R, Cooney DA, et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988; 168 (3): 1111-25
13. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998; 64 (3): 331-8
14. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/pediatric/PED_032405.pdf [Accessed 2005 Jun 28]
15. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004; 5 Suppl. 2: 61-86
16. US FDA, Center for Drug Evaluation and Research. A catalog of FDA-approved products [online]. Available from URL: http://www.accessdata.fda. gov/scripts/cder/drugsatfda/ [Accessed 2004 Mar 2]
17. Balis FM, Pizzo PA, Eddy J, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989; 114 (5): 880-4
18. Wintergerst U, Rolinski B, Vocks-Hauck M, et al. Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. Infection 1995; 23 (6): 344-8
19. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319 (14): 889-96
20. McKinney Jr RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med 1991; 324 (15): 1018-25
21. Mueller BU, Pizzo PA, Farley M, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr 1994; 125 (1): 142-6
22. Bakshi SS, Britto P, Capparelli E, et al. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 1997; 175 (5): 1039-50
23. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122 (1): 137-44
24. Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther 1999; 66 (1): 16-24
25. Mirochnick M, Capparelli E, Dankner W, et al. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42 (4): 808-12
26. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996; 174 (1): 16-25
27. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1998; 42 (12): 3187-92
28. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000; 44 (3): 590-7
29. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178 (5): 1327-33
30. Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001; 41 (7): 732-41
31. King JR, Nachman S, Yogev R, et al. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. Antivir Ther 2002; 7 (4): 267-70
32. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992; 165 (1): 99-104
33. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics 1994; 94 (5): 724-31
34. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000; 44 (4): 1029-34
35. Hoetelmans RM, van Heeswijk RP, Profijt M, et al. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 1998; 12 (17): F211-6
36. Keiser P, Turner D, Ramilo O, et al. An open-label pilot study of the efficacy and tolerability of once-daily didanosine versus twice-daily didanosine. Clin Infect Dis 1998; 27 (2): 400-1
37. Abreu T, Plaisance K, Rexroad V, et al. Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2000; 44 (5): 1375-6
38. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus: infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180 (5): 1536-41
39. Rongkavilit C, Thaithumyanon P, Chuenyam T, et al. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother 2001; 45 (12): 3585-90
40. Shyu WC, Knupp CA, Pittman KA, et al. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991; 50 (5 Pt 1): 503-7
41. Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol 1993; 33 (6): 568-73
42. Stevens RC, Rodman JH, Yong FH, et al. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses 2000; 16 (5): 415-21
43. Gibb D, Barry M, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br J Clin Pharmacol 1995; 39 (5): 527-30
44. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96 (2 Pt 1): 247-52
45. Kaul S, Kline MW, Church JA, et al. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2001; 45 (3): 758-63
46. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996; 97 (6 Pt 1): 886-90
47. HIV pharmacology news [online]. Available from URL: http://www. hivpharmacology.com [Accessed 2005 Jun 28]
48. Hughes W, McDowell JA, Shenep J, et al. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 1999; 43 (3): 609-15
49. Kline MW, Blanchard S, Fletcher CV, et al. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics 1999; 103 (4): E47
50. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48 (1): 124-9
51. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42 (9): 2380-4
52. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40 (12): 893-905
53. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174 (4): 713-21
54. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178 (2): 368-74
55. Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20 (8): 803-5
56. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999; 341 (25): 1874-81
57. Starr SE, Fletcher CV, Spector SA, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21 (7): 659-63
58. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15 (1): 71-5
59. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248 (4953): 358-61
60. Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30 Suppl. 2: S151-9
61. Mueller BU, Sleasman J, Nelon Jr RP, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998; 102 (1 Pt 1): 101-9
62. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998; 132 (3 Pt 1): 543-6
63. Gatti G, Vigano A, Sala N, et al. Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2000; 44 (3): 752-5
64. Burger DM, van Rossum AM, Hugen PW, et al. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001; 45 (3): 701-5
65. Fraaij PL, Bergshoeff AS, Van Rossum AM, et al. Changes in indinavir exposure over time: a case study in six HIV-1-infected children. J Antimicrob Chemother 2003; 52 (4): 727-30
66. van Rossum AM, de Groot R, Hartwig NG, et al. Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection. AIDS 2000; 14 (14): 2209-10
67. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28 (5): 1109-18
68. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther 2003; 8 (3): 215-22
69. Litalien C, Faye A, Compagnucci A, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003; 22 (1): 48-55
70. Schuster T, Linde R, Wintergerst U, et al. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing. AIDS 2000; 14 (10): 1466-8
71. van Heeswijk RP, Scherpbier HJ, de Koning LA, et al. The pharmacokinetics of nelfinavir in HIV-1-infected children. Ther Drug Monit 2002; 24 (4): 487-91
72. Gatti G, Castelli-Gattinara G, Cruciani M, et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis 2003; 36 (11): 1476-82
73. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14 (10): 1333-9
74. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25 (1): 73-80
75. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17 (8): 1157-65
76. Mueller BU, Nelson RP, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998 Mar; 101 (3 Pt 1): 335-43
77. Dumon C, Solas C, Thuret I, et al. Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther Drug Monit 2000; 22 (4): 402-8
78. Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2002; 71 (3): 122-30
79. King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41 (14): 1115-33
80. Scott T, Garris C, Rogers M, et al. Safety profile and tolerability of amprenavir in patients enrolled in an early access program. Clin Ther 2001; 23 (2): 252-9
81. Wintergerst U, Engelhorn C, Kurowski M, et al. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. AIDS 2000; 14 (12): 1866-8
82. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22 (3): 216-24
83. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2002 Jul; 21 (7): 653-9
84. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics 2002; 110 (2 Pt 1): E19
85. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 Suppl. 1: S5-37
86. Fraaij PL, Rakhmanina N, Burger DM, et al. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26: 122-6
87. Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002; 15 (1): 17-22
88. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18 (12): 825-34
89. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362 (9400): 2002-11
90. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63 (8): 741-53
91. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47 (2): 594-600
92. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46 (12): 3907-16
93. Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother 2002; 46 (2): 570-4
94. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47 (1): 350-9
95. 50) as predictor of virological response. AIDS 2003; 17 (2): 262-4
96. Gonzalez de Requena D, Gallego O, Valer L, et al. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20 (3): 275-8
97. Back DJ, Khoo SH. The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol 2003; 55 (5): 473-6
98. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359 (9300): 30-6
99. Nasi M, Borghi V, Pinti M, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003; 17 (11): 1696-8
100. Haas DW, Wu H, Li H, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 2003; 34 (3): 295-8